GSK Commits $30 Bn to U.S. R&D and Manufacturing Over Next Five Years

The investment includes a $1.2 billion allocation for advanced manufacturing facilities and AI-driven digital technologies.

GSK plc announced plans to invest $30 billion in research and development and supply chain infrastructure across the United States over the next five years.

The investment includes a $1.2 billion allocation for advanced manufacturing facilities and AI-driven digital technologies.

The $1.2 billion investment will fund construction of a new biologics “flex” factory at Upper Merion, Pennsylvania, aimed at developing medicines for respiratory diseases such as COPD and asthma, as well as cancer therapies including haematological, gynaecological, lung, and other solid tumors. Construction is scheduled to begin in 2026. The investment also covers enhancements across GSK’s five existing U.S. manufacturing sites in Pennsylvania, North Carolina, Maryland, and Montana, including new drug substance manufacturing and improved device and auto-injector capabilities.

Commenting on the announcement, GSK CEO Emma Walmsley said, “Alongside the many longstanding and vital shared interests that connect the U.K. and the United States, is advancing life sciences to get ahead of disease. This week’s State Visit brings together two countries that have led the world in science and healthcare innovation. We are proud to be part of both. Here in the U.K., we continue to invest in a significant manufacturing base and more than £1.5 billion in R&D every year. Today, we are committing to invest at least $30 billion in the United States over the next 5 years, further bolstering the already strong R&D and supply chain we have in the country. $1.2 billion of today’s announcement includes construction of an additional next-gen biologics ‘flex’ factory, powered by AI, advanced technologies, and expert talent to produce transformational new respiratory and cancer medicines for American patients.”

The broader $30 billion investment will support capital improvements across GSK’s U.S. supply chain, expand R&D drug discovery and development, and increase clinical trial activity. The company expects the U.S. to lead globally in the number of studies, sites, and clinical trial participants over the next five years.

Over the past year, GSK has already invested approximately $2 billion in U.S. manufacturing. In October 2024, a new $800 million facility in Marietta, Pennsylvania, began construction, doubling the site’s capacity. These initiatives will create hundreds of highly skilled jobs, supplementing GSK’s current U.S. workforce of around 15,000 employees.

Last year, GSK’s global supply chain delivered 1.7 billion packs of medicines and over 400 million vaccine doses, contributing to its objective of positively impacting the health of 2.5 billion people by 2030.

Stay tuned for more such updates on Digital Health News